Bank of America’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,800
| Closed | -$4.79K | – | 8579 |
|
|
2024
Q1 | $4.79K | Sell |
1,800
-3,973
| -69% | -$9.84K | ﹤0.01% | 7009 |
|
|
2023
Q4 | $13.7K | Sell |
5,773
-2,275
| -28% | -$4.03K | ﹤0.01% | 6865 |
|
|
2023
Q3 | $11.3K | Sell |
8,048
-5,579
| -41% | -$13.4K | ﹤0.01% | 6830 |
|
|
2023
Q2 | $41.3K | Sell |
13,627
-10,919
| -44% | -$42.1K | ﹤0.01% | 6522 |
|
|
2023
Q1 | $153K | Sell |
24,546
-5,306
| -18% | -$32.3K | ﹤0.01% | 6052 |
|
|
2022
Q4 | $182K | Sell |
29,852
-14,791
| -33% | -$120K | ﹤0.01% | 5962 |
|
|
2022
Q3 | $534K | Sell |
44,643
-13,306
| -23% | -$174K | ﹤0.01% | 5344 |
|
|
2022
Q2 | $731K | Buy |
57,949
+40,773
| +237% | +$379K | ﹤0.01% | 5167 |
|
|
2022
Q1 | $193K | Sell |
17,176
-9,550
| -36% | -$105K | ﹤0.01% | 6490 |
|
|
2021
Q4 | $473K | Buy |
26,726
+7,354
| +38% | +$155K | ﹤0.01% | 5916 |
|
|
2021
Q3 | $446K | Buy |
19,372
+14,109
| +268% | +$307K | ﹤0.01% | 5744 |
|
|
2021
Q2 | $123K | Sell |
5,263
-21,919
| -81% | -$558K | ﹤0.01% | 6405 |
|
|
2021
Q1 | $847K | Buy |
+27,182
| New | +$947K | ﹤0.01% | 4987 |
|
Bank of America's KNTE Position: Q2 2024 in Review
Bank of America sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 1,800 shares — an estimated $4.79K sold.
Bank of America first reported a position in KNTE in Q1 2021 and held it in 13 quarters. The position peaked at $847K in Q1 2021. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.
- Bank of America reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Bank of America sold 1,800 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $4.79K.
- Bank of America first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 13 quarters.
- Bank of America's Kinnate Biopharma Inc. Common Stock position peaked at $847K in Q1 2021.
- 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.
Based on Bank of America's 13F filing for Q2 2024, filed 14 Aug 2024.